CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma. Xiong S, Yue N, Zhang S, Xu Y, et al. Leuk Lymphoma 2026 Apr 29:1-21. doi: 10.1080/10428194.2026.2661769.

Read + Share

Amedeo Smart

Independent Medical Education

Xiong S, Yue N, Zhang S, Xu Y, et al. CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma. Leuk Lymphoma 2026 Apr 29:1-21. doi: 10.1080/10428194.2026.2661769.
PMID: 42054037